Incorporation of Protein Induced by Vitamin K Absence or Antagonist-II Into Transplant Criteria Expands Beneficiaries of Liver Transplantation for Hepatocellular Carcinoma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05907772 |
Recruitment Status :
Completed
First Posted : June 18, 2023
Last Update Posted : June 18, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Cancer of Liver | Other: No intervention |
Study Type : | Observational |
Actual Enrollment : | 522 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | Incorporation of Protein Induced by Vitamin K Absence or Antagonist-II Into Transplant Criteria Expands Beneficiaries of Liver Transplantation for Hepatocellular Carcinoma: A Multi-center Retrospective Cohort Study in China |
Actual Study Start Date : | August 27, 2022 |
Actual Primary Completion Date : | October 25, 2022 |
Actual Study Completion Date : | November 10, 2022 |
Group/Cohort | Intervention/treatment |
---|---|
Recipients with preoperative PIVKA-II≤240mAU/mL |
Other: No intervention
No intervention |
Recipients with preoperative PIVKA-II>240mAU/mL |
Other: No intervention
No intervention |
- Overall survival [ Time Frame: January 2015 to December 2020 ]the overall survival of liver transplant recipient with HCC
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- The HCC patients received LT with pre-operative PIVKA-II records performed from January 2015 to December 2020, whose clinicopathological data were registered in the CLTR.
Exclusion Criteria:
- (1) patients who received split LT or simultaneous transplantation, (2) patients who received re-transplantation, (3) patients with macroscopic portal vein tumor thrombosis or other macrovascular invasion, (4) patients with incomplete follow-up or incomplete important parameters records.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05907772
China, Zhejiang | |
Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine | |
Hangzhou, Zhejiang, China, 310003 |
Responsible Party: | Xiao Xu, Professor, Zhejiang University |
ClinicalTrials.gov Identifier: | NCT05907772 |
Other Study ID Numbers: |
CT2023-ZJU-OBS1 |
First Posted: | June 18, 2023 Key Record Dates |
Last Update Posted: | June 18, 2023 |
Last Verified: | June 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Carcinoma, Hepatocellular Liver Neoplasms Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms |
Adenocarcinoma Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Liver Diseases |